Speaker: Dr. Janet Pope, MD, FRCPC, Rheumatologist, St. Joseph’s Health Care London, London, ON
Moderator: Dr. Alyson Wong, MD, FRCPC, MHSc, University of British Columbia

ILD in RA and connective tissue diseases is a serious complication and needs identification and a multi-disciplinary treatment approach where we need to treat the underlying disease activity with immunesuppression and remove lung unfriendly medications, have general treatment such as exercise, treating hypoxemia, reducing aspiration (aggressive Rx of GERD), vaccinations and smoking cessation. Additionally, for progressive fibrotic ILD, anti-fibrotic medications have an important role to reduce lung progression. Methotrexate does not worsen ILD in rheumatic diseases but often patients have failed this treatment as they may develop ILD while on background disease modifying drugs. Co-management is important with excellent communication and a treatment plan that optimizes the expertise of both respirology and rheumatology. This state of the art lecture will include practical advice on patient cases, epidemiology and treatment for ILD in various patients such as rheumatoid arthritis, systemic sclerosis and other connective tissue diseases.

Learning objectives:

At the end of this presentation, attendees will be able to:

  • Review the workup of a patient with possible CTD-ILD to appraise the data in support of immunomodulatory therapy in CTD-ILD;
  • Explore the emerging role of anti-fibrotic therapy in CTD-ILD; and
  • Review best practices in co-management of ILD patients between the community and the ILD centre.

CanMEDS Roles Addressed: Collaborator, Health Advocate, Medical Expert

This session is co-developed by the Canadian Thoracic Society and Boehringer-Ingelheim and is planned to achieve scientific integrity, objectivity and balance.